] [3] Wang JY et al. EMBO J. 2001 20: 7333 [PMCID: PMC125787] [4] Marchand C et al. J Biol Chem. 2002 227: 12596 [PMID: 11805103] [5] Egbertson MS, Curr Leading Med Chem. 2007 7: 1251 [PMID: 17627556] [6] Summa V et al. J Med Chem. 2008 51: 5843 [PMID: 18763751] [7] Cooper DA et al. N Engl J Med. 2008 359: 355 [PMID: 18650513] [8] Malet I et al. Antimicrob Agents Chemother. 2008 52: 1351 [PMID: 18227187] [9] M ifiot M et al. Viruses. 2010 two: 1347 [PMID: 20706558] [10] Hare S et al. Proc Natl Acad Sci USA. 2010 107: 20057 [PMID: 21030679] [11] Billamboz M et al. Eur J Med Chem. 2011 46: 535 [PMID: 2118511]2013 Biomedical InformaticsBIOINFORMATION[12] De Luca L et al. Eur J Med Chem. 2011 46: 756 [PMID: 21227550] [13] Abd-Elazem IS et al. Antivir Res. 2002 55: 91 [PMID: 12076754] [14] Stewart JJP, MOPAC2009. http://OpenMOPAC.net.open access[15] Discovery Studio two.0, Accelrys, Inc, San Diego, CA, 2007. [16] Blanco JL et al. J Infect Dis. 2011 203: 1204 [PMID: 21459813] [17] da Silva D et al. J Antimicrob Chemother. 2010 65: 1262 [PMID: 20388636]Edited by P Kangueane Citation: Nunthaboot et al. Bioinformation 9(8): 426-431 (2013) License statement: That is an open-access write-up, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, supplied the original author and supply are crediteISSN 0973-2063 (on-line) 0973-8894 (print) Bioinformation 9(8): 426-431 (2013)2013 Biomedical InformaticsBIOINFORMATIONSupplementary material:Systems WT M522 -67.12 M532 -70.28 Y212R Y143R) M522 -67.73 (equivalent M532 -72.41 to N224H (equivalent to N155H) M522 M532 -54.58 -75.open accessTable 1: Interaction energies and distances ( of hydrogen bond, metal-ligand and – interactions with the docked configurations of ligands. S217H (equivalent to G140S/Q148H) Raltegravir -45.Rezvilutamide 39 M522 -60.Ripretinib 97 M532 -75.PMID:35126464 Interaction power (kcal/mol) Amino/Mg2+/DNA Asp128 Tyr129 Gly131 Gln186 Ala188 Phe190 ThrR2 (-, four.82) -Ligand interacting component (kind of interaction, O4 (hb, two.77) O4 (hb, 2.67) O9 (hb, three.03) O15 (hb, 2.92) O14 (hb, 2.94) O1 (hb, three.14) O1 (hb, 2.95) —-O2 (hb, two.95) O10 (hb, three.04) O15 (hb, two.94) O4 (hb, 3.05) O15 (hb,2.99) O16 (hb, 2.90) (-, R3 4.39)Tyr212/ArgRA (-, four.19)R3 (-, 5.30) O16 (hb,3.08)RA (cation, 3.46)His213 Gln215 Lys-O15 (hb,2.92) –O7 (hb, 2.86) O11 (hb, two.61) O13 (hb, 3.03) O9 (hb,2.72) -R1 (-, four.28)O5 (hb, two.95) O8 (hb, 2.97)-O9 (hb,3.25) R2 (-, 4.12) O1 (hb,two.84), O2 (hb,two.57) O5 (M, two.32), O7 (M, 2.44) O7 (M, three.11) O2 (hb, two.72)–F (hb, two.97)O16 (hb, three.00) -Val327 Mg2+ (1)O10 (M, 2.19) O2 (M, 3.12)O2 (M, three.22)O5 (M, two.23) O9 (M, two.40)O3 1.87) (M,O4 (M, 2.34)O15 (hb, 2.69) O9 (M, two.23)O2 2.58) O13 2.29) O13 3.92) O15 (hb,2.93) (M, (M, (M,O3 2.29)(M,Mg2+ (2) G4 C16 AO2 (M, two.23) O1 (M, two.19) -O2 (M, 2.45) O1 (M, two.14) -O2 (hb, three.04) R1 (-, three.93)O1 (hb, 2.99) O2 (hb, three.04) R1 (-, four.34)(M, O11 2.39) O1 (hb, 2.67) O2 (hb, 2.89) R1 (-, three.69) (hb, O10 3.00) RA (-, 4.22)O4 1.90) RA(M,O4 (M, 2.16) -O4 (M, 2.19) O4 (hb, two.99) O10 (hb, three.12) RA (-, 4.12)-(-, 4.93)RA (-, 3.72)Hb-hydrogen bond. M-metal-ligand. R1-the 1st catechol ring; R2-the 2nd catechol ring; R3-the 3rd catechol ring; RA-aromatic ring A.ISSN 0973-2063 (on the internet) 0973-8894 (print) Bioinformation 9(8): 426-431 (2013)2013 Biomedical Informatics
A greatest evidence topic was constructed according to a structured protocol. This protocol is fully described within the ICVTS [1].SEARCH STRATEGYMedline 1950 ovember 2011 and Embase 1974 une 2011 using the Dialog Datast.